CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
The purpose of this trial is to test if delgocitinib cream is effective at treating chronic hand eczema (CHE) and what side effects it may h...
Phase 3
Montreal, Canada and 39 other locations
The purpose of this study is to test if treatment with tralokinumab is safe and effectful to treat moderate-to-severe atopic hand eczema. Th...
Phase 3
Laval, Quebec, Canada and 73 other locations
the treatment of adults with moderate to severe Atopic Dermatitis (Eczema). OpSCF will be compared to a placebo.OpSCF or placebo will be adm...
Phase 2
Montréal, Quebec, Canada and 21 other locations
The purpose of this study is to evaluate the safety and tolerability of XmAb27564 following multiple doses among participants with plaque psoriasis a...
Phase 1
Montréal, Quebec, Canada and 7 other locations
The objective of this study is to assess the efficacy and safety of upadacitinib for the treatment of adolescent and adult participants with moderate...
Phase 3
Montréal, Quebec, Canada and 179 other locations
The primary objective of the study is to assess the long-term safety of dupilumab in pediatric participants with AD.The secondary objectives of the s...
Phase 3
Montreal, Quebec, Canada and 83 other locations
/TCI, compared with placebo in combination with TCS/TCI at Week 24, assessed using Eczema Area and Severity Index (EASI)....
Phase 3
Montreal, Quebec, Canada and 234 other locations
B7451015 is a Phase 3 study to evaluate Abrocitinib with or without Topical Medications in patients aged 12 years and older who have moderate to seve...
Phase 3
Montreal, Quebec, Canada and 558 other locations
This is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis. It will last up to 33 months.
Phase 3
Montreal, Quebec, Canada and 320 other locations
The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.
Phase 3
Montreal, Quebec, Canada and 487 other locations
Clinical trials
Research sites
Resources
Legal